Atorvastatin

• UNSPSC Description:

  Atorvastatin is an orally active HMG-CoA reductase inhibitor, has the ability to effectively decrease blood lipids. Atorvastatin inhibits human SV-SMC proliferation and invasion with IC50s of 0.39 μM and 2.39 μM, respectively[1][2][3].

• Target Antigen:

  Autophagy; HMG-CoA Reductase (HMGCR)

• Type:

  Reference compound

• Related Pathways:

  Autophagy;Metabolic Enzyme/Protease

• Applications:

  Metabolism-sugar/lipid metabolism

• Field of Research:

  Metabolic Disease; Inflammation/Immunology; Cancer

• Assay Protocol:

  https://www.medchemexpress.com/atorvastatin.html

• Purity:

  99.64

• Solubility:

  DMSO : ≥ 100 mg/mL

• Smiles:

  O=C(C(C(C1=CC=CC=C1)=C(C2=CC=C(F)C=C2)N3CC[C@@H](O)C[C@@H](O)CC(O)=O)=C3C(C)C)NC4=CC=CC=C4

• Molecular Weight:

  558.64

• References & Citations:

  [1]Nawrocki, J.W., et al., Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol, 1995. 15(5): p. 678-82.|[2]Santodomingo-Garzón T, et al. Atorvastatin inhibits inflammatory hypernociception. Br J Pharmacol. 2006 Sep;149(1):14-22.|[3]Turner NA, et al. Comparison of the efficacies of five different statins on inhibition of human saphenous vein smooth muscle cell proliferation and invasion. J Cardiovasc Pharmacol. 2007 Oct;50(4):458-61.|[4]Song XJ, et al. Atorvastatin inhibits myocardial cell apoptosis in a rat model with post-myocardial infarction heart failure by downregulating ER stress response. Int J Med Sci. 2011;8(7):564-72.|[5] Li Y, et al. Inhibition of endoplasmic reticulum stress signaling pathway: A new mechanism of statins to suppress the development of abdominal aortic aneurysm. PLoS One. 2017 Apr 3;12(4):e0174821.|[6]Ming-Bai Hu, et al. Atorvastatin induces autophagy in MDA-MB-231 breast cancer cells. Ultrastruct Pathol. Sep-Oct 2018;42(5):409-415.Acta Pharmacol Sin. 2024 Mar 8.|Arterioscler Thromb Vasc Biol. 2022 May;42(5):644-658.|Biomed Pharmacother. 2023 Aug 12;166:115323.|Biotechnol Bioeng. 2021 Sep 3.|Cancer Lett. 2022 Oct 19;215976.|Cell Cycle. 2019 Dec;18(23):3337-3350.|Cell Cycle. 2021 Sep 8;1-14.|Endocrinology. 2022 May 18;bqac076.|Eur J Pharmacol. 2023 Aug 1;956:175938.|Eur J Pharmacol. 2023 Dec 21:176261.|Exp Cell Res. 2023 Oct 23:113829.|Front Cell Dev Biol. 2022 Mar 3;10:806081.|Inflammation. 2024 Oct 31.|Int J Mol Sci. 2023 Apr 19, 24(8), 7492.|J Appl Toxicol. 2024 Apr 19|J Appl Toxicol. 2024 Apr 19.|J Mol Neurosci. 2021 Sep 26.|J Nat Prod. 2022 Jun 24.|J Neuroimmunol. 2020 Oct 24;350:577429.|J Tradit Complement Med. 2024 Mar 29.|Med Gas Res. 2024 March 28.|MedComm. 2024 Aug 31.|Mol Cell. 2021 Jul 1;81(13):2736-2751.e8.|Naunyn Schmiedebergs Arch Pharmacol. 2023 Jun 8.|Oncogene. 2022 Oct 31.|Orebro University. 2024.|Phytomedicine. 2023 Jul 26;119:154997.|Proteomics. 2023 May 4;e2300041.|Research Square Preprint. 2021 Dec.|Research Square Preprint. 2022 Jun.|Research Square Preprint. 2024 Apr 9.|Sci Rep. 2020 Jan 28;10(1):1308.|Signal Transduct Target Ther. 2023 Dec 25;8(1):457.|Adv Sci (Weinh). 2024 Jul 5:e2403451.|bioRxiv. 2024 Jul 3:2024.07.01.601474.|Cell Death Dis. 2021 May 13;12(5):482.|Endocrinology. 2018 May 1;159(5):2008-2021.|Free Radic Biol Med. 2024 May 2:S0891-5849(24)00435-0.|Front Bioeng Biotechnol. 2022 Mar 17;10:826093.|Pharmaceutics. 2022, 14(1), 176.|Eur J Med Chem. 2024 Dec 5.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  Launched

• CAS Number:

  134523-00-5